Verification of the Usefulness of an Assessment and Risk Control Sheet that Promotes Management of Cancer Drug Therapy.

Orie Honma ,M Tateba,S Wagatsuma,H Sonou,E Otsuka ,Yutaro Kubota ,Masaoki Kin ,Ken Shimada ,Takehiko Sambe ,Harumi Fukuchimoto ,Masakazu Murayama ,Kazuhiro Maki ,Takuya Tsunoda ,Hiroshi Toyoda ,Megumi Umeda ,M Hiruta ,Toshimitsu Tsurui ,Kiyoto Shiga ,Yoichiro Narikawa ,Koretsugu Ogata ,Chie Watanabe ,Yuya Hirasawa ,Hiroo Ishida ,Atsuo Kuramasu ,Atsushi Horiike ,Jun Kashiwazaki ,Masahiro Hosonuma ,Kiyoshi Yoshimura

doi:10.3389/fphar.2022.744916

Abstract

Background: Proper management of adverse events is crucial for the safe and effective implementation of anticancer drug treatment. Showa University Hospital uses our interview sheet (assessment and risk control [ARC] sheet) for the accurate evaluation of adverse events. On the day of anticancer drug treatment, a nurse conducts a face-to-face interview. As a feature of the ARC sheet, by separately describing the symptoms the day before treatment and the day of treatment and sharing the information on the medical record, it is possible to clearly determine the status of adverse events. In this study, we hypothesized that the usefulness and points for improvement of the ARC sheet would be clarified by using and evaluating a patient questionnaire. Methods: This study included 174 patients (144 at Showa University Hospital (Hatanodai Hospital) and 30 at Showa University Koto Toyosu Hospital (Toyosu Hospital) who underwent pre-examination interviews by nurses and received cancer chemotherapy at the outpatient center of Hatanodai and Toyosu Hospital. In the questionnaire survey, the ARC sheet’s content and quality, respondents’ satisfaction, structural strengths, and points for improvement were evaluated on a five-point scale. Results: The patient questionnaire received responses from 160 participants, including the ARC sheet use group (132 people) and the non-use group (28 people). Unlike the ARC sheet non-use group, the ARC sheet use group recognized that the sheet was useful to understand the adverse events of aphthous ulcers (p = 0.017) and dysgeusia (p = 0.006). In the satisfaction survey questionnaire, there was a high sense of security in the pre-examination interviews by nurses using the ARC sheet. Conclusions: The ARC sheet is considered an effective tool for comprehensively evaluating adverse events. Pre-examination interviews by nurses using ARC sheets accurately determined the adverse events experienced by patients with anxiety and tension due to confrontation with physicians.

Highlights

Cancer drug therapy is effective in controlling tumor progression, relieving symptoms, and prolonging survival
The ARC sheet has the feature of being able to evaluate a wide range of adverse events that are relatively frequent in cancer drug therapy
The adverse events listed on the sheet were comprehensively described regardless of the degree of CTCAE grade (Supplementary Table S3)

Summary

Introduction

Cancer drug therapy is effective in controlling tumor progression, relieving symptoms, and prolonging survival It is often associated with adverse events. Adverse events in patients undergoing cancer drug therapy may include subjective symptoms, many of which are not identified without asking the patient directly. In clinical practice, these symptoms are checked during medical examination and nursing care. One study has reported that a 5month extension in the overall survival time by using the PROCTCAE (Basch et al, 2017) It works by evaluating the most severe symptoms of one adverse event in the past week based on the patient’s answers to multiple questions regarding frequency, severity, and effects on daily life We hypothesized that the usefulness and points for improvement of the ARC sheet would be clarified by using and evaluating a patient questionnaire

Objectives

Methods

Results

Conclusion